• K. Siva Teja Reddy

The development and marketing authorization of oncology generic medicines in the European Union (EU) involves complex regulatory, scientific, quality and project-management requirements. Although the EU regulatory framework provides established requirements for generic medicinal products, effective coordination of regulatory activities, Chemistry, Manufacturing and Controls (CMC), bioequivalence (BE), documentation and submission-related activities remains an important challenge. The present study aimed to develop a risk-based project-management framework for efficient marketing authorization of oncology generic medicines in the EU by integrating regulatory requirements with systematic risk and project-management principles. A structured regulatory-document analysis was performed using applicable EU legislation, European Medicines Agency (EMA) guidelines, International Council for Harmonisation (ICH) guidelines and Common Technical Document (CTD) requirements. Regulatory requirements were identified, extracted and mapped to the relevant CTD modules. A regulatory requirement matrix and gap-analysis approach were used to identify areas of potential non-compliance or incomplete documentation. Identified risks were categorized into CMC, bioequivalence, documentation and project-management risks. Failure Mode and Effects Analysis (FMEA) was applied to prioritize risks based on Severity, Occurrence and Detectability, followed by Risk Priority Number (RPN) assessment. Critical-path analysis was subsequently performed to identify activities capable of influencing the overall regulatory project timeline. Regulatory intelligence and risk-mitigation strategies were incorporated to support proactive management of regulatory changes and high-priority risks. Based on the integrated assessment, a Risk-Based Regulatory Project-Management Framework was developed comprising regulatory intelligence, requirement identification, CTD mapping, gap analysis, risk identification, FMEA-based prioritization, critical-path analysis, risk mitigation, residual-risk assessment and submission-readiness evaluation. A regulatory case-study methodology was used to demonstrate the practical application of the proposed framework to an oncology generic development scenario.

European Union; Oncology Generic Drugs; Marketing Authorization; Regulatory Affairs; Regulatory Risk Management; Project Management; Quality Risk Management; Failure Mode and Effects Analysis; FMEA; Critical Path Analysis; Common Technical Document; CTD; Bioequivalence; Chemistry, Manufacturing and Controls; Regulatory Intelligence; Risk-Based Regulatory Framework.K. Siva Teja Reddy

"RISK-BASED PROJECT MANAGEMENT STRATEGIES FOR EUROPEAN UNION (EU) ONCOLOGY GENERIC DRUG APPROVAL: A REGULATORY FRAMEWORK FOR EFFICIENT MARKETING AUTHORIZATION", International Journal of Emerging Technologies and Innovative Research (www.jetir.org), ISSN:2349-5162, Vol.13, Issue 9, page no.d212-d223, September-2026, Available :http://www.jetir.org/papers/JETIR2609324.pdf

"RISK-BASED PROJECT MANAGEMENT STRATEGIES FOR EUROPEAN UNION (EU) ONCOLOGY GENERIC DRUG APPROVAL: A REGULATORY FRAMEWORK FOR EFFICIENT MARKETING AUTHORIZATION", International Journal of Emerging Technologies and Innovative Research (www.jetir.org | UGC and issn Approved), ISSN:2349-5162, Vol.13, Issue 9, page no. ppd212-d223, September-2026, Available at : http://www.jetir.org/papers/JETIR2609324.pdf